Navigation Links
Data from Clinical Studies of bioTheranostics' CancerTYPE ID® and Breast Cancer Index(SM) Molecular Diagnostic Tests Presented at ASCO 2011 Annual Meeting

SAN DIEGO, June 7, 2011 /PRNewswire/ -- bioTheranostics, Inc., a bioMerieux company that develops innovative oncology diagnostic tests to drive personalized treatment, reported today findings from clinical studies utilizing the company's CancerTYPE ID®, and Breast Cancer Index(SM). Data from the studies were presented this week at the American Society of Clinical Oncology (ASCO) 2011 Annual Meeting in Chicago.

On June 6, scientists from bioTheranostics and the Institut Gustave-Roussy (France) presented results from a study evaluating the utility of the Breast Cancer Index(SM) (BCI) for predicting pathologic complete response (pCR) in breast cancer patients treated with neoadjuvant chemotherapy.  In the study, patients with a high BCI score had a more favorable response to standard chemotherapies such as anthracycline and taxane (P=0.02).

"Patients determined as high-risk by BCI had a 10-fold greater probability of pCR with the chemotherapy regimen when compared to the low risk patients," said Mark Erlander, Ph.D., chief scientific officer, bioTheranostics. "These results suggest that BCI is predictive of chemotherapy response."

bioTheranostics also presented diagnostic utility data for CancerTYPE ID® from a study of 754 metastatic cancer cases.  The results showed that pre-CancerTYPE ID® pathological workup involved a mean of seven immunohistochemistry (IHC) stains to identify the cancer site of origin.  Increasing the number of IHC stains beyond seven lengthened the diagnostic process without improving the accuracy of the final result.

"Quickly and accurately diagnosing the site of origin is critical in the care of metastatic cancer patients," said Richard Ding, chief executive officer, bioTheranostics.  "This study illustrated that the current diagnostic process is not standardized and often time- consuming."  In the study, CancerTYPE ID required only five days of lab processing to predict a single primary site in more than 90 percent of the cases, and provided a more objective and informative diagnosis to physicians.

Finally, in collaboration with a group of international clinicians, bioTheranostics presented data from a study evaluating the utility of a novel P95 assay. The study assessed the assay's ability to identify the truncated form of the Her2 gene in Her2-positive breast cancer patients as a means to predict trastuzumab response.

About bioTheranostics

Advancing Molecular Diagnostics in Oncology

bioTheranostics discovers, develops and commercializes molecular diagnostic tests for cancer patients. Leveraging its unique expertise in expression profiling and algorithm development, bioTheranostics provides innovative tests to the oncology community. The company operates a CLIA-certified, CAP-accredited diagnostic service laboratory in San Diego, CA to perform its proprietary molecular diagnostic tests: Breast Cancer Index(SM), which is a prognostic test that provides quantitative risk assessment of distant recurrence in patients diagnosed with estrogen receptor positive and lymph node negative breast cancer; and the CancerTYPE ID® test, which uses the differential expression of 92 genes to aid in the determination of tumor site of origin. For more information call 1-858-587-5870 or visit

About bioMerieux

Advancing Diagnostics to Improve Public Health

A world leader in the field of in vitro diagnostics for over 45 years, bioMerieux is present in more than 150 countries through 39 subsidiaries and a large network of distributors. In 2010, revenues reached €1.357 billion with 87% of sales outside of France.

bioMerieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases and providing high medical value results for cancer screening and monitoring and cardiovascular emergencies. They are also used for detecting microorganisms in
agri-food, pharmaceutical and cosmetic products.

bioMerieux is listed on the NYSE Euronext Paris market (Symbol: BIM – ISIN: FR0010096479).

Other information can be found at

bioTheranostics Contacts

Tim Schofield
Tel: + 1 858 587 5890

Michele Parisi
Tel: + 1 925 864 5028

bioMerieux Contact

Koren Wolman-Tardy
Tel: + 011 33 6 13 94 51 14

SOURCE bioTheranostics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Tocagens First-in-Human Clinical Trial of Toca 511 Enrolling Patients with High Grade Glioma
2. Precision Therapeutics Presents Clinical Study Emphasizing the Role of ChemoFx® in Directing Chemotherapy in Gynecological Cancers
3. Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765
4. NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting
5. Late-Breaking ASCO Data Demonstrate Circulating Tumor Cells as Potential Biomarker for Metastatic Prostate Cancer Clinical Trials
6. Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting
7. Spherix Drug Candidate SPX-106 Shows Statistically Significant Reductions in Serum Triglycerides in Preclinical Testing
8. IDEV Technologies Announces Completion of SUPERB Clinical Trial Enrollment
9. Investment in Oncology Drug Development Remains Strong as 133 Companies Initiate Late-Stage Clinical Trials Representing a 21% Increase
10. PLC Ramps Up for U.S. Clinical Trial of RenalGuard®
11. Bionovo to Present the Clinical Promise of Menerba (MF101) for Postmenopausal Vasomotor Symptoms at World Congress on Menopause
Post Your Comments:
(Date:10/13/2015)... 2015  Nanomedical Diagnostics, a biotech company developing ... diagnostics, announces the completion of a Series A ... Ventures. --> ... monitoring and diagnostic platforms that empower individuals to ... will enable the company to commercially release AGILE ...
(Date:10/13/2015)... Oct. 9, 2015 Research and Markets ( ... "Kombucha Market by Types (Bacteria, Yeast, Mold, Others), Flavors ... Flowers, Others), & by Region - Forecasts to 2020" ... --> --> The global ... few years. In terms of value, the market is ...
(Date:10/13/2015)... Oct. 13, 2015   Micell Technologies , Inc. ... and II trials of its MiStent Sirolimus Eluting Absorbable ... ) were presented at the 27th Annual Transcatheter Cardiovascular ... San Francisco , October 11-15. TCT is the ... MiStent SES was designed to optimize vessel healing in ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... October 13, 2015 , ... Purdue University announced Tuesday (Oct. ... Initiative aimed at enhancing Purdue’s life sciences research and graduate education. The initiative ... , The investment will result in cohesive efforts across several colleges and is ...
(Date:10/13/2015)... ... 13, 2015 , ... "My friend's son suffers from eczema, and he had ... an inventor from Platteville, Colo. "I came up with this kit as a way ... to prevent a child from rubbing or scratching his or her face. This protects ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... ProText Kinetic ... X . With ProText Kinetic Panel, users can create energetic text animations in any ... preset into the Final Cut Pro X timeline and stylize the text. With intuitive ...
(Date:10/13/2015)... ... October 13, 2015 , ... Relay (, a technology ... today a significant contract that will provide its award-winning private messaging solution to ... the growing success of its Relay program, IBX Wire™, which now has over ...
(Date:10/13/2015)... ... October 13, 2015 , ... Leading Internet marketing product review ... "Publish Academy" training course . Singal's new program, in which he reveals his ... around the Internet are weighing in with reviews. , "Considering the fairly high ...
Breaking Medicine News(10 mins):